|FDA Announces Pharmacy Compounding Advisory Committee Members|
The U.S. Food and Drug Administration (FDA) today announced the membership of the Pharmacy Compounding Advisory Committee. The committee is comprised of 14 members - 12 voting and two non-voting - who will provide advice on scientific, technical and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Please click here for FDA's announcement, including the panel names.
IACP's Executive Vice President/CEO David G. Miller, RPh, comments, "We are glad to see that the FDA has put the Pharmacy Compounding Advisory Committee in place and we hope that this process will result in an implementation of DQSA that is more consistent with the intent of the law.
While we are pleased that the advisory committee finally has been announced and that the members are well-qualified scientifically, IACP has serious concerns about the lack of representation on the panel of actual practicing compounding pharmacists. IACP submitted 24 nominees, many with extensive real-life compounding practice experience, to the FDA and only one was selected."
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.